Detalles de la búsqueda
1.
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
BMC Infect Dis;
22(1): 245, 2022 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35279084
2.
Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection.
Therap Adv Gastroenterol;
17: 17562848241239547, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38529070
3.
Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTATM) Administered Under Enforcement Discretion to Patients With Clostridioides difficile Infection.
Open Forum Infect Dis;
10(5): ofad171, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37256213
4.
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Drugs;
82(15): 1527-1538, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36287379
5.
Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Drugs;
82(15): 1539, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36342618
Resultados
1 -
5
de 5
1
Próxima >
>>